CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Director Wei-Wu He acquired 200,000 shares of CASI Pharmaceuticals stock in a transaction that occurred on Friday, October 6th. The stock was acquired at an average cost of $1.83 per share, for a total transaction of $366,000.00. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Wei-Wu He also recently made the following trade(s):

  • On Monday, September 18th, Wei-Wu He acquired 173,500 shares of CASI Pharmaceuticals stock. The stock was acquired at an average cost of $1.75 per share, for a total transaction of $303,625.00.
  • On Tuesday, September 19th, Wei-Wu He acquired 207,502 shares of CASI Pharmaceuticals stock. The stock was acquired at an average cost of $1.75 per share, for a total transaction of $363,128.50.
  • On Friday, September 15th, Wei-Wu He acquired 315,327 shares of CASI Pharmaceuticals stock. The stock was acquired at an average cost of $1.33 per share, for a total transaction of $419,384.91.

Shares of CASI Pharmaceuticals, Inc. (NASDAQ CASI) traded up 15.03% during mid-day trading on Tuesday, hitting $2.22. 1,067,090 shares of the company traded hands. CASI Pharmaceuticals, Inc. has a 1-year low of $0.91 and a 1-year high of $2.35. The firm’s 50 day moving average price is $1.40 and its 200-day moving average price is $1.16. The stock’s market capitalization is $133.64 million.

CASI Pharmaceuticals (NASDAQ:CASI) last issued its earnings results on Monday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). On average, equities research analysts forecast that CASI Pharmaceuticals, Inc. will post ($0.15) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/10/casi-pharmaceuticals-inc-casi-director-acquires-366000-00-in-stock.html.

Several analysts recently weighed in on CASI shares. HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of CASI Pharmaceuticals in a research note on Friday, September 8th. Maxim Group reissued a “buy” rating and issued a $4.00 price objective on shares of CASI Pharmaceuticals in a research note on Friday, September 8th. Finally, ValuEngine raised shares of CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 15th.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.